Chengdu Easton Biopharmaceuticals Co Ltd (688513) — Tangible Net Worth Ratio
Chengdu Easton Biopharmaceuticals Co Ltd (688513) has a Tangible Net Worth Ratio of 90.3% as of March 2026. This metric is calculated by deducting intangible assets (CN¥298.64 Million) from net assets (CN¥3.09 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See 688513 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Chengdu Easton Biopharmaceuticals Co Ltd Tangible Net Worth Ratio (2013–2025)
This chart shows how Chengdu Easton Biopharmaceuticals Co Ltd's Tangible Net Worth Ratio has changed across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 90.3%, reflecting net assets of CN¥3.09 Billion with intangible assets of CN¥298.64 Million CNY. See Chengdu Easton Biopharmaceuticals Co Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Chengdu Easton Biopharmaceuticals Co Ltd from 2013 to 2025, covering 13 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Chengdu Easton Biopharmaceuticals Co Ltd (688513) market capitalisation.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 95.5% | CN¥6.66 Billion | CN¥301.22 Million | CN¥3.80 Billion | ▼ -0.5 pp |
| 2024 | 95.9% | CN¥2.70 Billion | CN¥109.37 Million | CN¥3.40 Billion | ▼ -0.8 pp |
| 2023 | 96.8% | CN¥2.60 Billion | CN¥84.46 Million | CN¥3.35 Billion | ▼ -0.1 pp |
| 2022 | 96.8% | CN¥2.44 Billion | CN¥77.01 Million | CN¥3.02 Billion | ▼ -1.3 pp |
| 2021 | 98.2% | CN¥2.29 Billion | CN¥41.76 Million | CN¥2.78 Billion | ▼ -0.2 pp |
| 2020 | 98.4% | CN¥2.10 Billion | CN¥34.22 Million | CN¥2.53 Billion | ▲ +3.4 pp |
| 2019 | 94.9% | CN¥697.44 Million | CN¥35.23 Million | CN¥987.08 Million | ▲ +1.1 pp |
| 2018 | 93.8% | CN¥582.19 Million | CN¥36.05 Million | CN¥789.69 Million | ▼ -2.9 pp |
| 2017 | 96.7% | CN¥445.28 Million | CN¥14.77 Million | CN¥591.98 Million | ▲ +0.4 pp |
| 2016 | 96.3% | CN¥389.79 Million | CN¥14.35 Million | CN¥520.22 Million | ▲ +1.6 pp |
| 2015 | 94.7% | CN¥268.21 Million | CN¥14.17 Million | CN¥311.63 Million | ▲ +1.8 pp |
| 2014 | 92.9% | CN¥203.25 Million | CN¥14.45 Million | CN¥283.10 Million | ▲ +1.7 pp |
| 2013 | 91.2% | CN¥168.62 Million | CN¥14.88 Million | CN¥254.86 Million | — |